CSIMarket Company Name, Ticker, Competitors, else..
 
Nektar Therapeutics  (NASDAQ: NKTR)
 

Nektar Therapeutics's Suppliers Performance

NKTR's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
NKTR Costs vs Sales of Suppliers Growth

• More on NKTR Suppliers






Nektar Therapeutics's Comment on Supply Chain


The company sources PEG reagents for the production of rezpegaldesleukin and NKTR-255 from Gannet BioChem following the sale of its manufacturing facility. Its contract manufacturers (CMOs) are required to adhere to current good manufacturing practices (cGMP) and comply with regulatory standards, including inspections by the FDA or equivalent agencies. Non-compliance by CMOs may lead to delays in clinical trials, commercialization, or marketing approvals, as well as potential sanctions or costly modifications to manufacturing processes. Such manufacturing delays due to regulatory issues could have a material adverse effect on the company's business and financial condition.

Nektar Therapeutics's Comment on Supply Chain


The company sources PEG reagents for the production of rezpegaldesleukin and NKTR-255 from Gannet BioChem following the sale of its manufacturing facility. Its contract manufacturers (CMOs) are required to adhere to current good manufacturing practices (cGMP) and comply with regulatory standards, including inspections by the FDA or equivalent agencies. Non-compliance by CMOs may lead to delays in clinical trials, commercialization, or marketing approvals, as well as potential sanctions or costly modifications to manufacturing processes. Such manufacturing delays due to regulatory issues could have a material adverse effect on the company's business and financial condition.







NKTR's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Nektar Therapeutics 1,905.94 54.59 -157.13 63
SUBTOTAL 0.00 0.00 0.00 -


Sources: Nektar Therapeutics's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Nektar Therapeutics’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.